GLP3-R: Mechanism of Action

Reported Mechanism

1. Triple Receptor Engagement

Retatrutide is described as engaging three class-B G-protein-coupled receptors with a single peptide sequence: the GIP receptor, the GLP-1 receptor, and the glucagon receptor.[1] This distinguishes it from dual GIP/GLP-1 agonism and from GLP-1-selective agonism, and it is the structural feature that defines the compound's research role.[8]

2. Incretin-Axis Signalling

GLP-1 and GIP receptor agonism act on the incretin axis, where insulinotropic activity is conditioned on ambient glucose. Hammoud and Drucker reviewed how the cardiometabolic actions of GIP and GLP-1 differ beyond the pancreas, and Samms et al. examined the mechanistic rationale for engaging GIP alongside GLP-1.[9][10]

3. Gastrointestinal Transit

Urva et al. reported that retatrutide delays gastric emptying, a pharmacodynamic readout shared across the incretin-agonist class and one of the standard endpoints used to characterize these compounds.[6]

4. Comparator Positioning

Coskun et al. previously characterized LY3298176 (tirzepatide) as the first unimolecular dual GIP/GLP-1 receptor agonist.[8] Placing the triple agonist alongside that dual agonist and a GLP-1-selective agonist gives investigators a graded series — one, two, or three receptors engaged by a single molecule — which is why this compound appears frequently as a reference arm in incretin pharmacology.[7]

Receptor-level and clinical findings summarized here were obtained with the pharmaceutical formulation under controlled study conditions. No conclusions about research-grade material are implied.